de-escalation

News

Stopping immunotherapy after two years does not affect NSCLC survival

No overall survival difference was found between patients with non-small cell lung cancer who stopped immune checkpoint inhibitors at two years and those continuing treatment indefinitely. The study, abstract 9101, presented at…

News

Radiotherapy can be safely omitted in older women with low-risk breast cancer

Leaving out radiotherapy does not affect survival after breast-conserving surgery in older women with low-risk hormone-receptor-positive early breast cancer. Ten-year outcomes for the PRIME II trial, published in the New England Journal…

Articles

Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access

Doctors at the Tata Memorial Hospital in Mumbai have shown that an ultra-low dose of the immunotherapy drug nivolumab significantly improves survival in patients with recurrent or newly diagnosed head and neck…